Who is sponsoring NCT04618367?

NCT04618367 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT04618367?

Interventions in NCT04618367: Hepatic arterial infusion chemotherapy, Lenvatinib, Sintilimab.

What condition does NCT04618367 study?

NCT04618367 studies Carcinoma, Hepatocellular, Liver Neoplasms, Sintilimab, Portal Vein Tumor Thrombus.

Is NCT04618367 still recruiting?

NCT04618367 is currently completed. Last updated 6 March 2024.

Last reviewed 2024-03-06 · How we verify

NCT04618367

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

Completed NA Last updated 6 March 2024

What this trial tests

NA trial testing Hepatic arterial infusion chemotherapy in Carcinoma, Hepatocellular in 30 participants. Completed in 30 December 2022.

Timeline

1 January 2021

Primary endpoint
30 December 2021

30 December 2022

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 January 2021
Primary completion	30 December 2021
Estimated completion	30 December 2022
Sites	1 location across China

Drugs / interventions tested

Hepatic arterial infusion chemotherapy
Lenvatinib (LENVATINIB) — full drug profile →
Sintilimab — full drug profile →

Conditions studied

Carcinoma, Hepatocellular — all drugs for Carcinoma, Hepatocellular →
Liver Neoplasms — all drugs for Liver Neoplasms →
Sintilimab — all drugs for Sintilimab →
Portal Vein Tumor Thrombus — all drugs for Portal Vein Tumor Thrombus →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 75, any sex, with Carcinoma, Hepatocellular or Liver Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study intends to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and Sintilimab for patients hepatocellular carcinoma and portal vein tumor thrombus.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
Ke Q, Xin F, Fang H, Zeng Y, et al · · 2022 · cited 40× · PMID 35677059 · DOI 10.3389/fimmu.2022.913464
Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy.
Petrazzuolo A, Maiuri MC, Zitvogel L, Kroemer G, et al · · 2022 · cited 23× · PMID 35655707 · DOI 10.1080/2162402x.2022.2077898
Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma.
Koh B, Tan DJH, Lim WH, Wong JSL, et al · · 2023 · cited 4× · PMID 37284696 · DOI 10.1080/2162402x.2023.2214478
Locoregional therapy combined with targeted therapy and immunotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis.
Jiang M, Chen C, Hu Y, Lin G, et al · · 2025 · cited 1× · PMID 41219316 · DOI 10.1038/s41598-025-23027-6

Verify or expand the search:

Other trials of Hepatic arterial infusion chemotherapy

Trials testing the same drug.

NCT06420440 — Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model · Phase 2 · recruiting
NCT06201065 — FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Ran · Phase 3 · recruiting
NCT05533892 — Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC · Phase 1 · unknown
NCT05003700 — Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma · Phase 2 · completed
NCT06333561 — HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma · recruiting

Other recruiting trials for Carcinoma, Hepatocellular

Currently open trials in the same condition.

NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen · Phase 1, PHASE2 · recruiting
NCT06742892 — A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to · Phase 2 · recruiting
NCT06422403 — A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers · Phase 2 · recruiting
NCT06349980 — A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or W · Phase 2 · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04618367 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 6 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04618367.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing